CA2946230C - Formulation liquide comprenant un composé neutralisant gm-csf - Google Patents

Formulation liquide comprenant un composé neutralisant gm-csf

Info

Publication number
CA2946230C
CA2946230C CA2946230A CA2946230A CA2946230C CA 2946230 C CA2946230 C CA 2946230C CA 2946230 A CA2946230 A CA 2946230A CA 2946230 A CA2946230 A CA 2946230A CA 2946230 C CA2946230 C CA 2946230C
Authority
CA
Canada
Prior art keywords
antibody
csf
seq
amino acid
set out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2946230A
Other languages
English (en)
Other versions
CA2946230A1 (fr
Inventor
Willow Diluzio
Phuong Nguyen
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority claimed from PCT/EP2015/059709 external-priority patent/WO2015169742A1/fr
Publication of CA2946230A1 publication Critical patent/CA2946230A1/fr
Application granted granted Critical
Publication of CA2946230C publication Critical patent/CA2946230C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des formulations aqueuses comprenant un composé neutralisant GM-CSF dans des concentrations d’au moins 20 mg/ml, un modificateur de tonicité, un tampon et un ou plusieurs tensioactifs, des acides aminés, des antioxydants et/ou des agents chélatants, la composition étant stable. Les composants de la formulation confèrent de préférence au composé neutralisant GM-CSF une stabilité à la conservation à long terme. Dans un aspect préféré, la formulation est pour utilisation en thérapie, de préférence pour utilisation dans le traitement de troubles inflammatoires et auto-immuns, de préférence, notamment des troubles allergiques et psoriasiques, ainsi que des troubles arthritiques et asthmatiques.
CA2946230A 2014-05-07 2015-05-04 Formulation liquide comprenant un composé neutralisant gm-csf Active CA2946230C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP14167405.1 2014-05-07
EP14167405 2014-05-07
US201461994319P 2014-05-16 2014-05-16
US61/994,319 2014-05-16
US201462043636P 2014-08-29 2014-08-29
US62/043,636 2014-08-29
PCT/EP2015/059709 WO2015169742A1 (fr) 2014-05-07 2015-05-04 Formulation liquide comprenant un composé neutralisant gm-csf

Publications (2)

Publication Number Publication Date
CA2946230A1 CA2946230A1 (fr) 2015-11-12
CA2946230C true CA2946230C (fr) 2025-07-08

Family

ID=

Similar Documents

Publication Publication Date Title
US11173208B2 (en) Liquid formulation comprising GM-CSF neutralizing compound
US10758621B2 (en) Liquid formulation comprising GM-CSF neutralizing compound
US9833410B2 (en) Lyophilized formulation comprising GM-CSF neutralizing compound
CA2946230C (fr) Formulation liquide comprenant un composé neutralisant gm-csf
HK40037400A (en) Liquid formulation comprising gm-csf neutralizing compound
HK1235316B (en) Liquid formulation comprising gm-csf neutralizing compound
HK1235316A1 (en) Liquid formulation comprising gm-csf neutralizing compound
ES2794449T3 (es) Formulación líquida que comprende un compuesto neutralizante del GM-CSF
HK1214761B (en) Liquid formulation comprising gm-csf neutralizing compound
EA040788B1 (ru) Жидкая композиция, содержащая соединение, нейтрализующее gm-csf